智通财经网·2025-12-12 13:23Core Viewpoint - Company Haohai Biological Technology (688366.SH) plans to acquire 8.4661 million shares of Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for RMB 38.3515 million, representing 19.8% of Ruiji's total share capital [1] Group 1: Company Overview - Jiangxi Ruiji was established in 2002 and specializes in the production and sales of biological amniotic membranes [1] - The main products include convex and concave amniotic membrane products, biological orthopedic amniotic membrane products, and wet biological amniotic membrane products, classified as Class III medical devices [1] Group 2: Market and Product Applications - The products are primarily used in orthopedic and ophthalmic fields, including tendon repair, treatment of ocular burns and injuries, and support after lacrimal duct obstruction [1] - The acquisition allows the company to gain distribution rights for Ruiji's products in China, entering the high-value medical device sector of biological amniotic membranes [1] Group 3: Strategic Implications - The acquisition is expected to effectively supplement the company's existing product portfolio and expand its business coverage in the ophthalmic and orthopedic sectors [1] - Ruiji's amniotic membrane materials possess human-derived biological characteristics, providing essential technical and material foundations for the company's research and development in regenerative medicine and tissue engineering [1] - This move is anticipated to drive subsequent product innovation and technological upgrades for the company [1]